Year |
Citation |
Score |
2022 |
Asuzu DT, Alvarez R, Fletcher PA, Mandal D, Johnson K, Wu W, Elkahloun A, Clavijo P, Allen C, Maric D, Ray-Chaudhury A, Rajan S, Abdullaev Z, Nwokoye D, Aldape K, et al. Pituitary adenomas evade apoptosis via noxa deregulation in Cushing's disease. Cell Reports. 40: 111223. PMID 36001971 DOI: 10.1016/j.celrep.2022.111223 |
0.425 |
|
2022 |
Hu Z, Viswanathan R, Cheng H, Chen J, Yang X, Huynh A, Clavijo P, An Y, Robbins Y, Silvin C, Allen C, Ormanoglu P, Martin S, Cornelius S, Saleh A, et al. Inhibiting WEE1 and IKK-RELA Crosstalk Overcomes TNFα Resistance in Head and Neck Cancers. Molecular Cancer Research : McR. PMID 35176168 DOI: 10.1158/1541-7786.MCR-21-0624 |
0.369 |
|
2021 |
Valencia JC, Erwin-Cohen RA, Clavijo PE, Allen C, Sanford ME, Day CP, Hess MM, Johnson M, Yin J, Fenimore JM, Bettencourt IA, Tsuneyama K, Romero ME, Klarmann KD, Jiang P, et al. Myeloid derived suppressive cell expansion promotes melanoma growth and severity of autoimmunity by inhibiting CD40/IL-27 regulation in macrophages. Cancer Research. PMID 34642183 DOI: 10.1158/0008-5472.CAN-21-1148 |
0.344 |
|
2021 |
Lee MY, Robbins Y, Sievers C, Friedman J, Abdul Sater H, Clavijo PE, Judd N, Tsong E, Silvin C, Soon-Shiong P, Padget MR, Schlom J, Hodge J, Hinrichs C, Allen C. Chimeric antigen receptor engineered NK cellular immunotherapy overcomes the selection of T-cell escape variant cancer cells. Journal For Immunotherapy of Cancer. 9. PMID 33741731 DOI: 10.1136/jitc-2020-002128 |
0.342 |
|
2020 |
Ye W, Gunti S, Allen CT, Hong Y, Clavijo PE, Van Waes C, Schmitt NC. ASTX660, an antagonist of cIAP1/2 and XIAP, increases antigen processing machinery and can enhance radiation-induced immunogenic cell death in preclinical models of head and neck cancer. Oncoimmunology. 9: 1710398. PMID 32002309 DOI: 10.1080/2162402X.2019.1710398 |
0.332 |
|
2019 |
Greene S, Robbins Y, Mydlarz WK, Huynh AP, Schmitt NC, Friedman J, Horn LA, Palena C, Schlom J, Maeda DY, Zebala JA, Clavijo PE, Allen C. Inhibition of MDSC trafficking with SX-682, a CXCR1/2 inhibitor, enhances NK cell immunotherapy in head and neck cancer models. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31848188 DOI: 10.1158/1078-0432.CCR-19-2625 |
0.302 |
|
2019 |
Patel P, Sun L, Robbins Y, Clavijo PE, Friedman J, Silvin C, Van Waes C, Cook J, Mitchell J, Allen C. Enhancing direct cytotoxicity and response to immune checkpoint blockade following ionizing radiation with Wee1 kinase inhibition. Oncoimmunology. 8: e1638207. PMID 31646086 DOI: 10.1080/2162402X.2019.1638207 |
0.366 |
|
2019 |
Sun L, Clavijo PE, Robbins Y, Patel P, Friedman J, Greene S, Das R, Silvin C, Van Waes C, Horn LA, Schlom J, Palena C, Maeda D, Zebala J, Allen CT. Inhibiting myeloid-derived suppressor cell trafficking enhances T cell immunotherapy. Jci Insight. 4. PMID 30944253 DOI: 10.1172/jci.insight.126853 |
0.341 |
|
2018 |
Das R, Coupar J, Clavijo PE, Saleh A, Cheng TF, Yang X, Chen J, Van Waes C, Chen Z. Lymphotoxin-β receptor-NIK signaling induces alternative RELB/NF-κB2 activation to promote metastatic gene expression and cell migration in head and neck cancer. Molecular Carcinogenesis. PMID 30488488 DOI: 10.1002/mc.22938 |
0.362 |
|
2018 |
Sun L, Moore E, Berman R, Clavijo PE, Saleh A, Chen Z, Van Waes C, Davies J, Friedman J, Allen CT. WEE1 kinase inhibition reverses G2/M cell cycle checkpoint activation to sensitize cancer cells to immunotherapy. Oncoimmunology. 7: e1488359. PMID 30288354 DOI: 10.1080/2162402X.2018.1488359 |
0.351 |
|
2017 |
Davis RJ, Moore EC, Clavijo PE, Friedman J, Cash HA, Chen Z, Silvin C, Van Waes C, Allen CT. Anti-PD-L1 efficacy can be enhanced by inhibition of myeloid derived suppressor cells with a selective inhibitor of PI3Kδ/γ. Cancer Research. PMID 28364000 DOI: 10.1158/0008-5472.CAN-16-2534 |
0.364 |
|
2016 |
Moore EC, Clavijo PE, Davis R, Cash HA, Van Waes C, Kim YJ, Allen CT. Established T-cell inflamed tumors rejected after adaptive resistance was reversed by combination STING activation and PD-1-pathway blockade. Cancer Immunology Research. PMID 27821498 DOI: 10.1158/2326-6066.CIR-16-0104 |
0.349 |
|
Show low-probability matches. |